Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.003175%
Leukocytosis01.02.01.0020.001764%
Leukopenia01.02.02.0010.003528%Not Available
Lichen planus23.03.08.0010.000706%Not Available
Lip dry07.06.01.0030.000706%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.003881%Not Available
Lipase increased13.05.01.0030.000706%
Liver disorder09.01.08.0010.003881%Not Available
Liver function test abnormal13.03.01.0130.007761%Not Available
Local swelling08.01.03.0130.001058%Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.0030.001058%Not Available
Lymphadenopathy01.09.01.0020.001411%Not Available
Lymphocyte count decreased13.01.06.0060.001411%
Lymphocytosis01.02.01.0030.000706%Not Available
Macule23.03.03.0370.002117%Not Available
Malaise08.01.01.0030.014464%
Mania19.16.02.0020.001411%
Melaena24.07.02.013; 07.12.02.0040.000706%Not Available
Mental impairment17.03.03.002; 19.21.02.0030.000706%Not Available
Metrorrhagia21.01.01.0060.001411%Not Available
Migraine24.03.05.003; 17.14.02.0010.001058%Not Available
Mood altered19.04.02.0070.001764%Not Available
Mood swings19.04.03.0010.001058%Not Available
Mouth ulceration07.05.06.0040.003881%Not Available
Movement disorder17.01.02.0100.000706%Not Available
Mucosal inflammation08.01.06.0020.001764%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.0010.003175%
Musculoskeletal pain15.03.04.0070.000706%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages